Superior Group of Companies (SGC) Q2 2026 earnings review
Cost Leverage Shines Through Mixed Segment Performance
Superior Group of Companies (SGC) delivered a mixed Q2. Consolidated revenue grew a stable 2.6% YoY to $147.8M, carried entirely by the Branded Products segment. The real story, however, was profitability. Stringent cost controls allowed Adjusted EBITDA to surge 26% YoY to $7.7M, and Adjusted EPS more than doubled to $0.21. The quarter was overshadowed by a $2.6M non-cash tradename impairment in Healthcare Apparel, a segment that slipped into a negative Adjusted EBITDA margin. Despite soft macro conditions, management maintained full-year guidance, relying heavily on a historically back-half weighted cadence and anticipated Contact Center pipeline conversions.
🐂 Bull Case
Stripping out the one-time impairment, adjusted net income jumped to $3.2M from $1.6M on just $3.8M of incremental revenue. The company is extracting significant margin leverage from previous SG&A optimization programs.
The core Branded Products segment continues to outpace the company average, growing 6.2% YoY. It now constitutes 66% of total revenue and generated $11.2M in Segment Adjusted EBITDA.
🐻 Bear Case
Healthcare Apparel went from a $792K profit last year to a $160K Segment Adjusted EBITDA loss, alongside a $2.6M tradename impairment charge. The turnaround here is stalling.
Contact Center revenue decelerated further, dropping 3.8% YoY to $23.1M. While management has touted a record pipeline in previous quarters, it has yet to materialize into top-line growth.
⚖️ Verdict: ⚪
Neutral. The aggressive cost management and Branded Products growth are commendable, but two of the three segments are actively shrinking. The company's reliance on a steep back-half recovery introduces significant execution risk.
Key Themes
Branded Products Remains the Growth Engine
Branded Products is the solitary pillar of top-line growth. Revenue grew 6.2% YoY to $98.4M. More impressively, Segment Adjusted EBITDA grew 25% YoY to $11.2M, highlighting strong margin capture in a fragmented market. This segment's stability is anchoring the entire enterprise.
Aggressive SG&A Cost Discipline
Selling and administrative expenses dropped from $52.2M to $51.3M YoY despite the revenue increase. This structural cost removal—stemming from previously announced $13M annualized savings programs—is yielding outsized bottom-line returns. Consolidated Adjusted EBITDA margins improved a full 100 basis points to 5.2%.
AI Integration Suppressing Expenses
SGC is leveraging proprietary AI tools like 'Guru Assist' in its Contact Centers to reduce agent training times and improve throughput. Similarly, the use of AI agents to automate time-consuming product selection and mockups in Branded Products is keeping headcount lean while driving volume.
Healthcare Apparel Narrative Contradicts Data
In prior quarters, management cited 'green shoots' in retail and expressed optimism following the appointment of a new segment President. The Q2 data completely reverses this positive narrative: revenue declined 3.9%, Segment Adjusted EBITDA flipped to negative (-$160K vs +$792K YoY), and the company was forced to take a $2.6M tradename impairment charge. The core brand equity is under severe pressure.
Contact Center Turnaround Delayed Again
The Contact Centers segment continues its decelerating trajectory, with revenues dropping 3.8% YoY to $23.1M. While management has historically pointed to a 'historical high' RFP pipeline, the prolonged sales cycles and lack of near-term conversion indicate that prospective clients are still highly hesitant to deploy capital.
Macro Pressures Force Back-Half Reliance
Management explicitly noted they are 'navigating through soft market conditions.' Reaffirming the aggressive FY26 EPS guidance ($0.54-$0.66) while reporting only $0.14 year-to-date (basic) implies an intensely back-half weighted business plan. If seasonal Q3/Q4 volume fails to materialize due to macroeconomic caution, guidance will be severely missed.
Other KPIs
Stable YoY. Gross profit rose slightly to $56.1M from $55.3M in the prior year quarter. Price increases and supply chain flexibility are effectively offsetting inflationary pressures and tariff impacts.
Improving. Total debt (current + long-term) stands at $82.0M against $22.8M in cash and equivalents. The company successfully paid down its revolving credit lines, reflecting solid free cash generation.
Accelerating dramatically compared to $2.9M provided in the first six months of 2025. This vast improvement was driven by positive working capital shifts, particularly a $10.6M swing in inventory management YoY.
Guidance
Stable. The midpoint of $578.5M implies a 2.2% YoY growth rate over FY25 ($566.2M). Given the 2.6% growth achieved in Q2, this guidance is realistic, provided Branded Products maintains its current momentum.
Accelerating. The midpoint of $0.60 represents a massive ~30% YoY increase over the $0.46 delivered in FY25. Achieving this will require strict adherence to the lowered SG&A run-rate and a seasonal boost in high-margin Branded Products orders in Q4.
Key Questions
Healthcare Tradename Impairment
What specifically triggered the $2.6M tradename impairment in Healthcare Apparel this quarter, and does it signal a permanent write-down of expectations for specific legacy brands like Wink?
Contact Center Conversions
We've heard about the 'record pipeline' in Contact Centers for several quarters. At what point in H2 2026 do you expect these RFPs to actually inflect into YoY revenue growth?
M&A Strategy Post-Impairment
With the balance sheet generating solid operating cash, and given the operational struggles in Healthcare and Contact Centers, will M&A focus exclusively on bolstering the outperforming Branded Products division?